JR Vyas, CMD of Dishman Pharma in an interview to CNBC-TV18 spoke about the outlook for the company going forward. The company is on track to meet their revenue guidance for the year and is targeting a debt reduction of Rs 100 cr in FY16 via cash accruals.
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!